 |
|
 |
 |
|
WEDNESDAY,
AUGUST 8, 2007
Advances
in Immunotherapy
for Malignant
Melanoma
A
complimentary
dinner meeting
Washington, DC
Chair:
F. Stephen Hodi
Jr., MD
Dana Farber Cancer
Institute
Boston, Massachusetts
Click
here to register
for this program
|
 |
|
F A C
U L T
Y |
 |
|
|
Keith T. Flaherty, MD
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania
|
F. Stephen Hodi Jr., MD
Dana Farber Cancer Institute
Boston, Massachusetts
|
William H. Sharfman, MD
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland
|
|
|
|
S C I
E N T
I F I
C
A G E
N D A
|
|
|
6:00 pm
Registration
and reception
6:30 pm
Introduction
to the
biology
of melanoma
F.
Stephen Hodi Jr., MD
6:45
pm
Immunotherapy:
Harnessing
the immune
response to cancer
William
H. Sharfman, MD
7:15 pm
Overcoming
immunologic
tolerance to melanoma: Targeting CTLA-4
F.
Stephen Hodi Jr., MD
7:45
pm
Enhancing
the immune
response to melanoma: Vaccines and other novel biologics to stimulate and target
the immune response
Keith
T. Flaherty, MD
8:15 pm
Question
and answer
session
8:30 pm
Adjourn
|
|
|
|
C O N
T I N
U I N
G M
E D I
C A L
E D U
C A T
I O N |
|
|
|
Imedex
Accreditation
Services,
LLC
is
accredited
by
the
Accreditation
Council
for
Continuing
Medical
Education
to
provide
continuing
medical
education
for
physicians.
Imedex
Accreditation
Services,
LLC
designates
this
educational
activity
for
a
maximum
2.0
of
AMA
PRA
Category
1
Credit(s)TM.
Physicians
should
only
claim
credit
commensurate
with
the
extent
of
their
participation
in
the
activity.
|
|
|
|
W H O
S H O
U L D
A T T
E N D
? |
|
|
|
This
educational
activity
is
specifically
designed
for
medical
oncologists,
dermatologists,
and
other
physicians,
physicians-in-training,
and
healthcare
professionals
interested
in
and/or
involved
in
the
care
of
patients
with
melanoma
and
its
consequences.
No
specialized
knowledge
or
skill
other
than
general
familiarity
with
internal
medicine,
oncology,
or
dermatology
is
required
for
successful
participation
in
this
activity.
|
|
|
|
O B J
E C T
I V E
S |
|
|
|
After
successfully
completing
this
educational
activity,
participants
should
be
able
to:
- Describe
the
basic concepts
of immunotherapy
and how
each type
can be
used as
a treatment modality in
oncology
-
Discuss
the
role
immune
tolerance
plays
in
allowing
the
growth
and
spread
of
cancer
cells
-
Explain
the
specific
role
of
CTLA-4
in
maintaining
immune
tolerance
and
how
inhibiting
its
function
can
be
used
in
the
treatment
of
malignant
melanoma
-
Compare
and
contrast
emerging
biological
agents,
primarily
vaccines
and
cytokines,
that
are
used
to
stimulate
and
target
a
patient’s
own
immune
response
against
a
tumor
and
are
currently
in
trials
for
use
against
melanoma
|
|
|
|
|
R E G
I S T
R A T
I O N |
|
|
|
Click
here
to
register
for
this
program
You may register online by August 7,
2007
or by calling Imedex at +1 (678) 242 0906. Registration
confirmations
will be issued before the meeting. This is a complimentary
dinner meeting and space
is limited. To confirm your attendance, please register by August 7, 2007.
|
|
|
|
G
E N E
R A L
I N F
O R M
A T I
O N |
|
|
|
Meeting
Location
B.
Smith’s
Union
Station
50
Massachusetts
Ave.
NE
(Columbus
Circle)
Washington,
DC
20002
Tel.:
+1
(202)
289-6188
|
|
|
|
O R G
A N I
Z E R |
|
|
|
|
|
©
2007 Imedex Accreditation
Services. LLC.
All rights reserved.
Reproduction in
whole or part
is prohibited
without prior
written consent
from Imedex and
contributing faculty.
|
